Eli Lilly Published P-I/II Trial (BRUIN) Results of Pirtobrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the NEJM
Shots:
- The P-I/II trial evaluating pirtobrutinib, a non-covalent (reversible) BTK inhibitor in adult patients with CLL or SLL previously treated with a BTK inhibitor
- In prior BTKi & patients treated with prior BTK + BCL2 inhibitors, ORR (73.3% & 70.0%), ORR incl. PR-L (82.2% & 79.0%), CR (4% & 0%), PR (176% & 70%), PR-L (22% & 9%), SD (26% & 11%), m-PFS (19.6 & 16.8mos.), median follow-up (19.4 & 18.2mos.). In a subgroup analysis of BCL2 inhibitor naïve patients, ORR incl. PR-L (84.4%) & m-PFS was 22.1mos.
- 87.4% received 1 dose of pirtobrutinib at RP2D of 200mg, qd & the median time on treatment (16.5mos.), the safety profile was consistent with prior reported data, treatment-related AEs led to dose reductions & permanent discontinuations in 4.7% & 2.8%, respectively
Ref: PR Newswire | Image: Eli Lilly
Related News:- Eli Lilly Reports (CHALLENGE-MIG) Trial Results of Emgality (galcanezumab-gnlm) for the Prevention of Episodic Migraine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
